The indication was restricted to only patients with DMD who are 4 years of age and older with a confirmed mutation in the DMD gene; the indication for non-ambulatory patients with DMD was removed.

Zymeworks surges on positive Phase 3 Ziihera data in HER2-positive cancer. Discover key catalysts and what’s next for ZYME ...

Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration ...

Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved ...

A car’s build sheet is based on the car’s unique vehicle identification number (VIN). It lists both standard and optional ...

What It Means If ‘See Agent’ Is Printed on Your Boarding Pass Kate Gosselin budgets Christmas for 8 kids 'to the penny' after ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...

The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...

The agency is cautioning patients about the risk of serious, possibly fatal, liver injuries and has limited the gene therapy's use to ambulatory patients.

Money market funds in Kenya have quietly transformed from niche capital market products into the most powerful savings engines in the country ...

Presented detailed efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Me ...